USA - NASDAQ:OM - US6901452069 - Common Stock
The current stock price of OM is 6.22 USD. In the past month the price decreased by -53.51%. In the past year, price decreased by -47.64%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.45 | 221.04B | ||
| ISRG | INTUITIVE SURGICAL INC | 66.45 | 205.11B | ||
| BSX | BOSTON SCIENTIFIC CORP | 34.75 | 151.88B | ||
| SYK | STRYKER CORP | 27.62 | 139.05B | ||
| IDXX | IDEXX LABORATORIES INC | 56.5 | 57.00B | ||
| BDX | BECTON DICKINSON AND CO | 13.11 | 54.18B | ||
| EW | EDWARDS LIFESCIENCES CORP | 33.14 | 50.00B | ||
| RMD | RESMED INC | 25.5 | 36.84B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 15.99 | 33.52B | ||
| PODD | INSULET CORP | 71.4 | 22.97B | ||
| DXCM | DEXCOM INC | 31.25 | 22.80B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 10.94 | 17.53B |
Outset Medical, Inc. engages in the provision of dialysis solutions to patients and healthcare providers. The company is headquartered in San Jose, California and currently employs 354 full-time employees. The company went IPO on 2020-09-15. The company offers Tablo Hemodialysis System (Tablo), which is a single enterprise solution for hemodialysis, comprised of a compact console with integrated water purification, on-demand dialysate production and advanced software and connectivity capabilities. The company designed Tablo from the ground up to be a single enterprise solution that can be utilized across the continuum of care, allowing dialysis to be delivered anytime, anywhere, and by virtually anyone. Tablo comprises various components, including Tablo Console, Tablo Cartridge, and Tablo Data Ecosystem. Tablo Console is a proprietary, compact, mobile and versatile machine consisting of an integrated water purification, on-demand dialysate production system and simple-to-use touchscreen interface with 3D animations. The company also offers various key platforms, such as TabloHub, a customer-facing portal; MyTablo, a patient-facing portal, and TabloDash, an internal data analytics platform.
OUTSET MEDICAL INC
3052 Orchard Drive
San Jose CALIFORNIA 95134 US
CEO: Leslie Trigg
Employees: 354
Phone: 16692318200
Outset Medical, Inc. engages in the provision of dialysis solutions to patients and healthcare providers. The company is headquartered in San Jose, California and currently employs 354 full-time employees. The company went IPO on 2020-09-15. The company offers Tablo Hemodialysis System (Tablo), which is a single enterprise solution for hemodialysis, comprised of a compact console with integrated water purification, on-demand dialysate production and advanced software and connectivity capabilities. The company designed Tablo from the ground up to be a single enterprise solution that can be utilized across the continuum of care, allowing dialysis to be delivered anytime, anywhere, and by virtually anyone. Tablo comprises various components, including Tablo Console, Tablo Cartridge, and Tablo Data Ecosystem. Tablo Console is a proprietary, compact, mobile and versatile machine consisting of an integrated water purification, on-demand dialysate production system and simple-to-use touchscreen interface with 3D animations. The company also offers various key platforms, such as TabloHub, a customer-facing portal; MyTablo, a patient-facing portal, and TabloDash, an internal data analytics platform.
The current stock price of OM is 6.22 USD. The price decreased by -48.47% in the last trading session.
OM does not pay a dividend.
OM has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
OM stock is listed on the Nasdaq exchange.
OUTSET MEDICAL INC (OM) has a market capitalization of 110.53M USD. This makes OM a Micro Cap stock.
OUTSET MEDICAL INC (OM) will report earnings on 2026-01-05, after the market close.
ChartMill assigns a fundamental rating of 2 / 10 to OM. OM may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months OM reported a non-GAAP Earnings per Share(EPS) of -15.48. The EPS increased by 55.9% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -34.26% | ||
| ROE | -63.87% | ||
| Debt/Equity | 0.61 |
13 analysts have analysed OM and the average price target is 26.27 USD. This implies a price increase of 322.27% is expected in the next year compared to the current price of 6.22.
For the next year, analysts expect an EPS growth of 83.58% and a revenue growth 10.17% for OM